Literature DB >> 22338072

PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis.

Julia Perttilä1, Carolina Huaman-Samanez, Sandrine Caron, Kimmo Tanhuanpää, Bart Staels, Hannele Yki-Järvinen, Vesa M Olkkonen.   

Abstract

Liver fat is increased in carriers of the minor G allele in rs738409 (I148M amino acid substitution) in patatin-like phospholipase domain-containing 3 (PNPLA3)/adiponutrin. We studied transcriptional regulation of PNPLA3 in immortalized human hepatocytes (IHH) and human hepatoma cells (HuH7) and the impact of PNPLA3 I148M mutant on hepatocyte triglyceride metabolism. Studies in IHH showed that silencing of the carbohydrate response element-binding protein (ChREBP) abolished induction of PNPLA3 mRNA by glucose. Glucose-dependent binding of ChREBP to a newly identified carbohydrate response element in the PNPLA3 promoter was demonstrated by chromatin immunoprecipitation. Adenoviral overexpression of mouse ChREBP in IHH failed to induce PNPLA3 mRNA. [(3)H]acetate or [(3)H]oleate incorporation with 1-h pulse labeling or 18-h [(3)H]oleate labeling in HuH7 cells showed no effect of PNPLA3 I148M on triglyceride (TG) synthesis in the absence of free fatty acid (FFA) loading. Increased [(3)H]oleate accumulation into triglycerides in I148M-expressing cells was observed after 18 h of labeling in the presence of 200 μM FFA-albumin complexes. This was accompanied by increased PNPLA3 protein levels. The rate of hydrolysis of [(3)H]TG during lipid depletion was decreased significantly by PNPLA3 I148M. Our results suggest that PNPLA3 is regulated in human hepatocytes by glucose via ChREBP. PNPLA3 I148M enhances cellular accumulation of [(3)H]TG in the presence of excess FFA, which is known to stabilize PNPLA3 protein. These data do not exclude an effect of PNPLA3 I148M on hepatocyte lipogenesis but show that the mutant increases the stability of triglycerides.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22338072     DOI: 10.1152/ajpendo.00125.2011

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  37 in total

Review 1.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

2.  Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.

Authors:  Panu K Luukkonen; Auli Nick; Maarit Hölttä-Vuori; Christoph Thiele; Elina Isokuortti; Susanna Lallukka-Brück; You Zhou; Antti Hakkarainen; Nina Lundbom; Markku Peltonen; Marju Orho-Melander; Matej Orešič; Tuulia Hyötyläinen; Leanne Hodson; Elina Ikonen; Hannele Yki-Järvinen
Journal:  JCI Insight       Date:  2019-08-22

3.  Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes.

Authors:  Sandrine Caron; Carolina Huaman Samanez; Hélène Dehondt; Maheul Ploton; Olivier Briand; Fleur Lien; Emilie Dorchies; Julie Dumont; Catherine Postic; Bertrand Cariou; Philippe Lefebvre; Bart Staels
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272

Review 4.  PNPLA3 genetic variation in alcoholic steatosis and liver disease progression.

Authors:  Felix Stickel; Jochen Hampe; Eric Trépo; Christian Datz; Stefano Romeo
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

5.  PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

Review 6.  Pediatric fatty liver disease: role of ethnicity and genetics.

Authors:  Pierluigi Marzuillo; Emanuele Miraglia del Giudice; Nicola Santoro
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 7.  Association between PNPLA3 rs738409 polymorphisms and risk of hepatocellular carcinoma and its development in patients with cirrhosis: a meta-analysis.

Authors:  Shijie Zhang; Hexing Wu; Xiangwei Wu; Webo Lian; Yanchao Wang; Xiaozhao Zhang; Xinyu Peng
Journal:  Int J Clin Exp Med       Date:  2015-05-15

8.  PNPLA3 mediates hepatocyte triacylglycerol remodeling.

Authors:  Hanna Ruhanen; Julia Perttilä; Maarit Hölttä-Vuori; You Zhou; Hannele Yki-Järvinen; Elina Ikonen; Reijo Käkelä; Vesa M Olkkonen
Journal:  J Lipid Res       Date:  2014-02-07       Impact factor: 5.922

Review 9.  The genetics of NAFLD.

Authors:  Quentin M Anstee; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-24       Impact factor: 46.802

10.  PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans.

Authors:  Andreas Peter; Marketa Kovarova; Silvio Nadalin; Tomas Cermak; Alfred Königsrainer; Fausto Machicao; Norbert Stefan; Hans-Ulrich Häring; Erwin Schleicher
Journal:  Diabetologia       Date:  2014-06-29       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.